The most persistent myths about schizophrenia are that it means a split personality, that people who have it are usually violent, that bad parenting causes it, and that nobody recovers. None of them survives the research. Schizophrenia is a psychotic disorder that affects well under 1% of people at any one time, is largely heritable, and responds best to medication combined with family, psychological and vocational support, started early.
Each of those myths makes the same mistake. It treats schizophrenia as a fixed identity, a kind of person, rather than an illness whose course varies widely and can be changed by care. The evidence describes something else: an inherited vulnerability in how the developing brain wires itself, pushed over a threshold by exposures such as heavy cannabis use and childhood adversity, with outcomes shaped by how soon and how well people are treated. That is why stigma is a clinical problem and not only a social one. Anything that teaches people to hide symptoms works against one of the few outcome factors anyone can change: the time between the first psychotic symptoms and real treatment.

What schizophrenia is, and how common it really is
Under DSM-5 criteria, a diagnosis of schizophrenia requires at least two of five symptom types for a significant part of a month: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. At least one of the two has to be delusions, hallucinations or disorganized speech. Signs of the illness must last at least six months, functioning at work, in relationships or in self-care must have dropped, and other explanations, including substances, medical illness and mood disorders with psychotic features, have to be ruled out.1 DSM-5 also retired the familiar subtypes, such as paranoid and catatonic schizophrenia, because they did a poor job of explaining how different one patient is from the next.2
Clinicians usually sort the symptoms into three groups. Positive symptoms are experiences added to ordinary life: hearing voices, holding fixed false beliefs, speech that slides from one topic to another. Negative symptoms are subtractions. A 2017 review summarizing expert consensus lists five of them, blunted affect, alogia (reduced speech), anhedonia, asociality and avolition, and stresses that some of what looks like a negative symptom is actually secondary to medication effects, depression or the psychosis itself.3 Cognitive symptoms affect attention, working memory and planning. They are easy to miss, they are linked to how well someone functions day to day, and antipsychotics do little for them. Several studies have found cognitive decline beginning almost a decade before the first psychotic episode.4
The figure most websites repeat, including an earlier version of this page, is that schizophrenia affects 1% of the population. That overstates it. The Global Burden of Disease study put the age-standardized point prevalence at 0.28% in 2016, or about 21 million people worldwide.5 Systematic reviews from John McGrath’s group in Queensland found a median lifetime prevalence of 4 per 1,000 people and a lifetime morbid risk, the chance of developing it at some point, of about 7 per 1,000.6, 7 Incidence varies about fivefold between study sites, runs higher in men (a rate ratio of 1.4 to 1), is higher among migrants than native-born people, and varies with urbanicity.7 Onset is usually in late adolescence or early adulthood; participants in the U.S. RAISE first-episode trial averaged 23 years old.8
Psychotic experiences are far more common than the disorder. A conservative meta-analysis of 61 cohorts put their prevalence at 7.2% of the general population. For about 80% of people who reported them, the experiences faded over time, and 7.4% went on to develop a psychotic disorder.9 Hearing a voice once, or holding an odd belief for a while, is not a diagnosis.
Myth: schizophrenia means a split personality
The Swiss psychiatrist Eugen Bleuler introduced the word schizophrenia in 1908, in a paper on the prognosis of what Emil Kraepelin had called dementia praecox, and Bleuler’s term eventually replaced Kraepelin’s.10 He built it from Greek roots meaning split and mind. What he meant was a splitting of psychological functions, so that thinking, feeling and will stop working together, not a single person housing several personalities.
The confusion is not entirely the public’s fault. A centenary review of Bleuler’s 1911 monograph argues that splitting was central to his concept, that the concept had close ties to ideas about dissociation, and that the popular “split personality” reading therefore has some historical basis.11 Carl Jung, who trained under Bleuler at the Burghölzli hospital in Zurich, took an even more psychological approach in his 1907 study of dementia praecox, translated into English in 1909, which treated psychotic speech as organized by emotionally charged complexes rather than as random noise.12 The idea that symptoms carry personal content worth understanding still shapes good therapy for psychosis.
Modern diagnosis draws the line clearly. Dissociative identity disorder, once called multiple personality disorder, involves distinct identity states and gaps in memory; it is a dissociative disorder, not a psychotic one, and our guide to dissociative identity disorder covers it in detail. The two can still be confused because voice hearing occurs in both. In one small comparison study, voices in dissociative identity disorder were more likely than voices in schizophrenia to start before age 18, to number more than two, and to include both child and adult voices.13 That overlap is one reason a careful assessment matters more than a symptom checklist, and why we treat dissociation and lost time as their own clinical question.
Everyday misuse of the word keeps the myth alive. In a random sample of 1,740 U.S. newspaper articles from 1996 and 1997, 28% of the articles that mentioned schizophrenia used it as a metaphor, compared with 1% of those that mentioned cancer.14 The people who carry the diagnosis notice. In a 27-country survey of 732 people with schizophrenia, 47% reported discrimination in making or keeping friends, 43% from their own families, and 72% felt they had to conceal the diagnosis.15
Myth: people with schizophrenia are dangerous
The honest answer is more complicated than either the myth or the usual rebuttal, and an earlier version of this page oversimplified it. A 2009 meta-analysis by Seena Fazel and colleagues pooled 20 studies covering 18,423 people with schizophrenia and other psychoses. It found a real but modest increase in violence: an odds ratio of about 2.1 in people without substance misuse, rising to 8.9 in people who also misused alcohol or drugs. That second figure was similar to the risk in people who misused substances without any psychosis, and the authors concluded that most of the excess risk appears to be mediated by substance use. The same review found a much larger relative increase for homicide, a rare outcome (odds ratio 19.5).16 Treating addiction is therefore part of violence prevention, and our piece on the neuroscience of addiction looks at how substance use takes hold in the brain.
Population figures put the risk in proportion. In Swedish national registers covering 13 years, people who had been hospitalized with schizophrenia and other psychoses accounted for 5.2% of violent crime, about one in twenty offenses.17 And the harm runs the other way more often. In a review of U.S. studies, 2% to 13% of outpatients with severe mental illness had committed violence over periods of six months to three years, while 20% to 34% had been violently victimized.18 Treatment matters here as well: in placebo-controlled relapse-prevention trials, aggressive acts were less common among people kept on antipsychotics (2% versus 12%), though the authors rated that evidence as limited.19
The larger danger is to the person with the illness. A reexamination of the suicide literature estimated that 4.9% of people with schizophrenia die by suicide, usually near the onset of illness.20 A meta-analysis of 11 studies found that schizophrenia shortens life by an average of 14.5 years, and that the gap does not appear to have narrowed over time.21 If someone is in danger now, call or text 988, and see our list of crisis resources in Birmingham.
Myth: bad parenting causes schizophrenia
In the middle of the twentieth century, American psychiatry often blamed mothers. The phrase “schizophrenogenic mother” is usually traced to a 1948 paper by the psychoanalyst Frieda Fromm-Reichmann, and the idea spread widely before collapsing; a 1996 history notes that its former promoters went from calling it a half truth to calling it a myth.22, 23 We look at what the family theories of that era got right and wrong, including Gregory Bateson’s double bind, in schizophrenia, trauma and the double bind.
The evidence that replaced mother-blaming is mostly genetic. In the nationwide Danish twin register, covering 31,524 twin pairs, heritability was estimated at 79%. Yet when one identical twin had schizophrenia, the other was affected only about a third of the time (33%), which means genes set the vulnerability without settling the outcome.24 A 2022 genome-wide study of 76,755 people with schizophrenia and 243,649 controls found 287 risk loci, concentrated in genes active in neurons and involved in building and running synapses.25
One of the clearest mechanistic leads involves the immune system. Common variants of the complement component 4 genes are associated with schizophrenia in proportion to how much they raise expression of C4A, and in mice C4 helps eliminate synapses during development, which may help explain the reduced synapse numbers found in the disorder.26 Work in the developing mouse visual system showed that microglia, the brain’s resident immune cells, engulf synapses through a complement-dependent pathway.27 That is why researchers have become interested in microglia and the immune side of mental illness, although none of this has produced a treatment yet.
Many upstream risks seem to converge on dopamine. Oliver Howes and Shitij Kapur’s 2009 synthesis argued that genes, pregnancy and birth complications, stress, trauma and drug use all feed into increased presynaptic dopamine function in the striatum, which may produce psychosis by lending ordinary perceptions and thoughts a misplaced sense of importance, what they call aberrant salience. In their account, current antipsychotics act downstream of that abnormality rather than on its causes.28
Environment still counts. In a 2016 meta-analysis, the heaviest cannabis users had about 3.9 times the odds of schizophrenia or another psychotic outcome compared with nonusers, with risk rising by level of use, although the authors note that causation cannot be established with certainty.29 Childhood adversity is also associated with psychosis. A 2012 meta-analysis of 36 case-control, cohort and cross-sectional studies found that people exposed to abuse, neglect, bullying or the death of a parent had about 2.8 times the odds of psychotic symptoms or illness, an association that held across study designs.30 A clinician’s account of whether some schizophrenia is better understood as complex PTSD looks at how trauma and psychosis overlap in practice.
Parenting does not cause schizophrenia, but the emotional climate at home does affect relapse. Across 27 studies, families high in what researchers call expressed emotion, meaning criticism, hostility or emotional over-involvement, reliably predicted relapse.31 That finding reflects the strain of living with a serious illness, not blame, and it explains why family intervention helps. In a Cochrane review of 53 trials, family intervention was associated with fewer relapses (risk ratio 0.55 across the 32 trials that reported relapse, or about seven people treated to prevent one relapse) and better medication adherence, though the reviewers warn that poor trial quality may overestimate the effect.32
Myth: nobody recovers from schizophrenia
Recovery numbers depend on the definition, and pessimists and optimists tend to quote the one that suits them. The strict version comes from a 2013 meta-analysis of 50 studies that required improvement in both symptoms and social functioning, with at least one of those sustained for two years. By that standard the median recovery rate was 13.5%, about one in seven, and it had not risen over the decades studied.33 An earlier version of this page cited that paper as evidence that many people lead fulfilling lives. It shows something more sobering, and more specific.
First-episode samples look better. Across 79 studies and more than 19,000 patients followed after a first episode of psychosis, 58% reached remission and 38% met recovery criteria. Recovery rates held steady after the first two years, which the authors read as evidence that a progressive, deteriorating course is not typical.34
Many people living with serious mental illness, schizophrenia included, describe recovery in personal rather than clinical terms: building a life worth living, with or without some symptoms. A systematic review of 97 papers on personal recovery in mental illness distilled five processes, abbreviated CHIME: connectedness, hope and optimism, identity, meaning in life, and empowerment.35 These are not soft extras. They are what psychosocial treatment is trying to rebuild.
Timing matters. Longer duration of untreated psychosis is modestly but consistently associated with worse symptoms and functioning, and the association is not explained by how well people were doing before they became ill.36 In the U.S. RAISE trial, 34 community clinics in 21 states were randomized either to NAVIGATE, a team-based coordinated specialty care program that combined medication management, individual therapy, family education and help with work or school, or to usual community care. Over two years, NAVIGATE participants stayed in treatment longer and improved more in quality of life, symptoms and involvement in work and school, and the gains were largest for people whose untreated psychosis had lasted less than the median of 74 weeks.8 A meta-analysis of 10 randomized trials found early intervention services better than usual care on all 13 outcomes it could analyze, including fewer hospitalizations and less dropout from treatment.37
Fact: medication and psychosocial care work best together
Antipsychotic treatment began with chlorpromazine, synthesized in France in December 1950 and introduced into psychiatry in 1952.38 The standard split into first-generation and second-generation drugs is less useful than it sounds. An earlier version of this page said the second-generation drugs emerged in the 1990s. That is true of most of them in the U.S., but clozapine, usually counted as the first of them, was already in use in Europe by 1975, when a cluster of agranulocytosis cases in Finland stalled it, and it reached the U.S. market in 1990.39
A 2019 network meta-analysis of 32 oral antipsychotics across 402 trials in adults with acute, multi-episode schizophrenia found that every drug reduced overall symptoms more than placebo on average (for six the difference was not statistically significant), that most efficacy differences between drugs were gradual rather than clear-cut, and that side effects differed more markedly: weight gain, sedation, movement problems, prolactin elevation and heart-rhythm effects varied widely from drug to drug. The authors rated confidence in much of that evidence as low or very low.40 The U.S. CATIE trial, which randomized 1,493 people with chronic schizophrenia, found that 74% stopped their assigned drug within 18 months. The older drug perphenazine performed about as well as quetiapine, risperidone and ziprasidone, and olanzapine lasted longest but caused the most weight gain and metabolic change.41
For people who have stabilized, staying on medication lowers relapse risk substantially. Across 65 placebo-controlled trials, 27% of people kept on antipsychotics relapsed within a year, compared with 64% of those switched to placebo, at the cost of more weight gain, movement disorders and sedation.19 For people whose symptoms persist through repeated trials of other antipsychotics, the established option is clozapine. In the 1988 trial that established its use, 30% of treatment-resistant patients responded to clozapine compared with 4% on chlorpromazine.42 It requires regular blood tests because it can cause a dangerous loss of white blood cells.
None of this is a reason to start, stop or switch a medication on your own. Choosing an antipsychotic means weighing benefit against side effects in light of a person’s history, health and preferences, which is how the authors of the 2019 network meta-analysis framed it, and that decision belongs with a psychiatrist or other prescriber. Antipsychotics are not a cure; they reduce symptoms and relapse while people take them.
Psychological treatment helps, though less dramatically than its advocates sometimes claim. Cognitive behavioral therapy for psychosis (CBTp) reduced positive symptoms more than treatment as usual in a 2018 network meta-analysis of 53 trials of psychological treatments added to antipsychotics, with effects in the small-to-medium range depending on the comparison.43 A 2014 meta-analysis that examined sources of bias found an overall effect of 0.33, which shrank sharply in trials where outcome assessors did not know who had received therapy.44 The earlier version of this page also said CBT prevents relapse; these trials measured symptoms, and the clearer relapse evidence comes from family intervention.32 CBTp also differs from the familiar work of identifying and challenging cognitive distortions. The therapist does not try to argue someone out of a belief. The work is collaborative: looking at the evidence together, reducing distress, and testing what happens when the person responds to a voice differently.
Other psychosocial treatments have their own evidence. Across 27 trials, social skills training improved negative symptoms by about as much as CBTp improves positive symptoms.45 Supported employment, which helps people look for competitive jobs right away and keeps supporting them once they are hired, alone or combined with other training, was the most effective route to paid work for adults with severe mental illness in a Cochrane network meta-analysis of 48 trials, on moderate- to low-quality evidence.46 The original page credited it with better self-esteem and symptom control; that review measured employment. Cognitive remediation, structured practice in attention, memory and problem-solving, improved cognition (d = 0.29) and overall functioning (d = 0.22) across 130 trials, and worked best with an active, trained therapist and alongside broader rehabilitation.47 It is one of the more concrete examples of neuroplasticity being put to work in serious mental illness, with modest effects.
What this looks like in therapy
There is no reliable online test for schizophrenia, and a page like this one cannot tell you whether you have it. Voices, suspicion and unusual beliefs can come from sleep loss, substances, medical illness, severe depression or bipolar disorder, trauma and dissociation, as well as from a primary psychotic disorder. Sorting those apart takes an in-person evaluation, ideally including a psychiatrist. Even among people who meet criteria for clinical high risk, with milder or brief psychotic symptoms, most do not develop psychosis within three years: in a meta-analysis of 27 studies, 22% had transitioned after one year and 36% after three. That is still far above the risk in the general population.48 The point of an early evaluation is not a label. It is to shorten the time to help if help is needed.
In an outpatient practice like ours, therapy for someone with schizophrenia is one part of a team. It does not replace psychiatric care, or a coordinated specialty care program after a first episode. The work usually starts with safety and with the practical things that tend to make symptoms worse, such as poor sleep, cannabis and other substances, and stress, and with making sure the person is connected to a prescriber. From there it tends to include:
- Curiosity about what the voices say and what the beliefs mean to the person: when a voice gets louder, what it seems to want, and what happens when the person answers it differently. Jung argued for this kind of attention more than a century ago; CBTp gives it a structured, testable form.
- Family sessions that lower criticism and over-involvement, teach the early warning signs of relapse, and make a plan for them.
- Attention to trauma. In one randomized trial of 155 people with psychotic disorders and PTSD, standard prolonged exposure and EMDR reduced PTSD symptoms without more serious adverse events than a waiting list.49
- Work, school and relationships: supported returns to study or employment, social skills practice, and the slow rebuilding of connectedness, hope, identity, meaning and empowerment.
- Coordination. With consent, the therapist shares what they see about side effects, sleep and early warning signs with the prescriber.
What therapy should not do is promise to replace medication, treat psychosis as purely psychological, or treat a diagnosis as the whole person. Every myth at the top of this page makes that last mistake.
If you or someone you love is living with psychosis or a schizophrenia diagnosis and wants therapy alongside psychiatric care, you can contact Taproot to ask whether we are a good fit. If symptoms are new, start with a medical and psychiatric evaluation, and if someone is in danger, call or text 988.
References
- American Psychiatric Association. (2013). Schizophrenia spectrum and other psychotic disorders. In Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Publishing. https://doi.org/10.1176/appi.books.9780890425596.dsm02
- Tandon, R., Gaebel, W., Barch, D. M., Bustillo, J., Gur, R. E., Heckers, S., Malaspina, D., Owen, M. J., Schultz, S., Tsuang, M., Van Os, J., & Carpenter, W. (2013). Definition and description of schizophrenia in the DSM-5. Schizophrenia Research, 150(1), 3–10. https://doi.org/10.1016/j.schres.2013.05.028
- Marder, S. R., & Galderisi, S. (2017). The current conceptualization of negative symptoms in schizophrenia. World Psychiatry, 16(1), 14–24. https://doi.org/10.1002/wps.20385
- Kahn, R. S., & Keefe, R. S. (2013). Schizophrenia is a cognitive illness: Time for a change in focus. JAMA Psychiatry, 70(10), 1107–1112. https://doi.org/10.1001/jamapsychiatry.2013.155
- Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018). Global epidemiology and burden of schizophrenia: Findings from the Global Burden of Disease Study 2016. Schizophrenia Bulletin, 44(6), 1195–1203. https://doi.org/10.1093/schbul/sby058
- Saha, S., Chant, D., Welham, J., & McGrath, J. (2005). A systematic review of the prevalence of schizophrenia. PLoS Medicine, 2(5), Article e141. https://doi.org/10.1371/journal.pmed.0020141
- McGrath, J., Saha, S., Chant, D., & Welham, J. (2008). Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews, 30(1), 67–76. https://doi.org/10.1093/epirev/mxn001
- Kane, J. M., Robinson, D. G., Schooler, N. R., Mueser, K. T., Penn, D. L., Rosenheck, R. A., Addington, J., Brunette, M. F., Correll, C. U., Estroff, S. E., Marcy, P., Robinson, J., Meyer-Kalos, P. S., Gottlieb, J. D., Glynn, S. M., Lynde, D. W., Pipes, R., Kurian, B. T., Miller, A. L., . . . Heinssen, R. K. (2016). Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. American Journal of Psychiatry, 173(4), 362–372. https://doi.org/10.1176/appi.ajp.2015.15050632
- Linscott, R. J., & van Os, J. (2013). An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: On the pathway from proneness to persistence to dimensional expression across mental disorders. Psychological Medicine, 43(6), 1133–1149. https://doi.org/10.1017/s0033291712001626
- Maatz, A., & Hoff, P. (2014). The birth of schizophrenia or a very modern Bleuler: A close reading of Eugen Bleuler’s ‘Die Prognose der Dementia praecox’ and a re-consideration of his contribution to psychiatry. History of Psychiatry, 25(4), 431–440. https://doi.org/10.1177/0957154×14546606
- Moskowitz, A., & Heim, G. (2011). Eugen Bleuler’s Dementia praecox or the group of schizophrenias (1911): A centenary appreciation and reconsideration. Schizophrenia Bulletin, 37(3), 471–479. https://doi.org/10.1093/schbul/sbr016
- Jung, C. G. (1909). The psychology of dementia praecox. Journal of Nervous and Mental Disease Publishing. https://doi.org/10.1037/10783-000 (Original work published 1907)
- Dorahy, M. J., Shannon, C., Seagar, L., Corr, M., Stewart, K., Hanna, D., Mulholland, C., & Middleton, W. (2009). Auditory hallucinations in dissociative identity disorder and schizophrenia with and without a childhood trauma history: Similarities and differences. Journal of Nervous and Mental Disease, 197(12), 892–898. https://doi.org/10.1097/nmd.0b013e3181c299ea
- Duckworth, K., Halpern, J. H., Schutt, R. K., & Gillespie, C. (2003). Use of schizophrenia as a metaphor in U.S. newspapers. Psychiatric Services, 54(10), 1402–1404. https://doi.org/10.1176/appi.ps.54.10.1402
- Thornicroft, G., Brohan, E., Rose, D., Sartorius, N., Leese, M., & INDIGO Study Group. (2009). Global pattern of experienced and anticipated discrimination against people with schizophrenia: A cross-sectional survey. The Lancet, 373(9661), 408–415. https://doi.org/10.1016/s0140-6736(08)61817-6
- Fazel, S., Gulati, G., Linsell, L., Geddes, J. R., & Grann, M. (2009). Schizophrenia and violence: Systematic review and meta-analysis. PLoS Medicine, 6(8), Article e1000120. https://doi.org/10.1371/journal.pmed.1000120
- Fazel, S., & Grann, M. (2006). The population impact of severe mental illness on violent crime. American Journal of Psychiatry, 163(8), 1397–1403. https://doi.org/10.1176/ajp.2006.163.8.1397
- Choe, J. Y., Teplin, L. A., & Abram, K. M. (2008). Perpetration of violence, violent victimization, and severe mental illness: Balancing public health concerns. Psychiatric Services, 59(2), 153–164. https://doi.org/10.1176/ps.2008.59.2.153
- Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2063–2071. https://doi.org/10.1016/s0140-6736(12)60239-6
- Palmer, B. A., Pankratz, V. S., & Bostwick, J. M. (2005). The lifetime risk of suicide in schizophrenia: A reexamination. Archives of General Psychiatry, 62(3), 247–253. https://doi.org/10.1001/archpsyc.62.3.247
- Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017). Years of potential life lost and life expectancy in schizophrenia: A systematic review and meta-analysis. The Lancet Psychiatry, 4(4), 295–301. https://doi.org/10.1016/s2215-0366(17)30078-0
- Fromm-Reichmann, F. (1948). Notes on the development of treatment of schizophrenics by psychoanalytic psychotherapy. Psychiatry, 11(3), 263–273. https://doi.org/10.1080/00332747.1948.11022688
- Hartwell, C. E. (1996). The schizophrenogenic mother concept in American psychiatry. Psychiatry, 59(3), 274–297. https://doi.org/10.1080/00332747.1996.11024768
- Hilker, R., Helenius, D., Fagerlund, B., Skytthe, A., Christensen, K., Werge, T. M., Nordentoft, M., & Glenthøj, B. (2018). Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin register. Biological Psychiatry, 83(6), 492–498. https://doi.org/10.1016/j.biopsych.2017.08.017
- Trubetskoy, V., Pardiñas, A. F., Qi, T., Panagiotaropoulou, G., Awasthi, S., Bigdeli, T. B., Bryois, J., Chen, C. Y., Dennison, C. A., Hall, L. S., Lam, M., Watanabe, K., Frei, O., Ge, T., Harwood, J. C., Koopmans, F., Magnusson, S., Richards, A. L., Sidorenko, J., . . . O’Donovan, M. C. (2022). Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 604(7906), 502–508. https://doi.org/10.1038/s41586-022-04434-5
- Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., Genovese, G., Rose, S. A., Handsaker, R. E., Schizophrenia Working Group of the Psychiatric Genomics Consortium, Daly, M. J., Carroll, M. C., Stevens, B., & McCarroll, S. A. (2016). Schizophrenia risk from complex variation of complement component 4. Nature, 530(7589), 177–183. https://doi.org/10.1038/nature16549
- Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012). Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron, 74(4), 691–705. https://doi.org/10.1016/j.neuron.2012.03.026
- Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III. The final common pathway. Schizophrenia Bulletin, 35(3), 549–562. https://doi.org/10.1093/schbul/sbp006
- Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42(5), 1262–1269. https://doi.org/10.1093/schbul/sbw003
- Varese, F., Smeets, F., Drukker, M., Lieverse, R., Lataster, T., Viechtbauer, W., Read, J., van Os, J., & Bentall, R. P. (2012). Childhood adversities increase the risk of psychosis: A meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophrenia Bulletin, 38(4), 661–671. https://doi.org/10.1093/schbul/sbs050
- Butzlaff, R. L., & Hooley, J. M. (1998). Expressed emotion and psychiatric relapse: A meta-analysis. Archives of General Psychiatry, 55(6), 547–552. https://doi.org/10.1001/archpsyc.55.6.547
- Pharoah, F., Mari, J., Rathbone, J., & Wong, W. (2010). Family intervention for schizophrenia. Cochrane Database of Systematic Reviews, 2010(12), Article CD000088. https://doi.org/10.1002/14651858.cd000088.pub3
- Jääskeläinen, E., Juola, P., Hirvonen, N., McGrath, J. J., Saha, S., Isohanni, M., Veijola, J., & Miettunen, J. (2013). A systematic review and meta-analysis of recovery in schizophrenia. Schizophrenia Bulletin, 39(6), 1296–1306. https://doi.org/10.1093/schbul/sbs130
- Lally, J., Ajnakina, O., Stubbs, B., Cullinane, M., Murphy, K. C., Gaughran, F., & Murray, R. M. (2017). Remission and recovery from first-episode psychosis in adults: Systematic review and meta-analysis of long-term outcome studies. British Journal of Psychiatry, 211(6), 350–358. https://doi.org/10.1192/bjp.bp.117.201475
- Leamy, M., Bird, V., Le Boutillier, C., Williams, J., & Slade, M. (2011). Conceptual framework for personal recovery in mental health: Systematic review and narrative synthesis. British Journal of Psychiatry, 199(6), 445–452. https://doi.org/10.1192/bjp.bp.110.083733
- Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Archives of General Psychiatry, 62(9), 975–983. https://doi.org/10.1001/archpsyc.62.9.975
- Correll, C. U., Galling, B., Pawar, A., Krivko, A., Bonetto, C., Ruggeri, M., Craig, T. J., Nordentoft, M., Srihari, V. H., Guloksuz, S., Hui, C. L. M., Chen, E. Y. H., Valencia, M., Juarez, F., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., . . . Kane, J. M. (2018). Comparison of early intervention services vs treatment as usual for early-phase psychosis: A systematic review, meta-analysis, and meta-regression. JAMA Psychiatry, 75(6), 555–565. https://doi.org/10.1001/jamapsychiatry.2018.0623
- López-Muñoz, F., Alamo, C., Cuenca, E., Shen, W. W., Clervoy, P., & Rubio, G. (2005). History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry, 17(3), 113–135. https://doi.org/10.1080/10401230591002002
- Crilly, J. (2007). The history of clozapine and its emergence in the US market: A review and analysis. History of Psychiatry, 18(1), 39–60. https://doi.org/10.1177/0957154×07070335
- Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G., & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet, 394(10202), 939–951. https://doi.org/10.1016/s0140-6736(19)31135-3
- Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., Hsiao, J. K., & Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353(12), 1209–1223. https://doi.org/10.1056/nejmoa051688
- Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789–796. https://doi.org/10.1001/archpsyc.1988.01800330013001
- Bighelli, I., Salanti, G., Huhn, M., Schneider-Thoma, J., Krause, M., Reitmeir, C., Wallis, S., Schwermann, F., Pitschel-Walz, G., Barbui, C., Furukawa, T. A., & Leucht, S. (2018). Psychological interventions to reduce positive symptoms in schizophrenia: Systematic review and network meta-analysis. World Psychiatry, 17(3), 316–329. https://doi.org/10.1002/wps.20577
- Jauhar, S., McKenna, P. J., Radua, J., Fung, E., Salvador, R., & Laws, K. R. (2014). Cognitive-behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. British Journal of Psychiatry, 204(1), 20–29. https://doi.org/10.1192/bjp.bp.112.116285
- Turner, D. T., McGlanaghy, E., Cuijpers, P., van der Gaag, M., Karyotaki, E., & MacBeth, A. (2018). A meta-analysis of social skills training and related interventions for psychosis. Schizophrenia Bulletin, 44(3), 475–491. https://doi.org/10.1093/schbul/sbx146
- Suijkerbuijk, Y. B., Schaafsma, F. G., van Mechelen, J. C., Ojajärvi, A., Corbière, M., & Anema, J. R. (2017). Interventions for obtaining and maintaining employment in adults with severe mental illness, a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(9), Article CD011867. https://doi.org/10.1002/14651858.cd011867.pub2
- Vita, A., Barlati, S., Ceraso, A., Nibbio, G., Ariu, C., Deste, G., & Wykes, T. (2021). Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 78(8), 848–858. https://doi.org/10.1001/jamapsychiatry.2021.0620
- Fusar-Poli, P., Bonoldi, I., Yung, A. R., Borgwardt, S., Kempton, M. J., Valmaggia, L., Barale, F., Caverzasi, E., & McGuire, P. (2012). Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk. Archives of General Psychiatry, 69(3), 220–229. https://doi.org/10.1001/archgenpsychiatry.2011.1472
- van den Berg, D. P., de Bont, P. A., van der Vleugel, B. M., de Roos, C., de Jongh, A., Van Minnen, A., & van der Gaag, M. (2015). Prolonged exposure vs eye movement desensitization and reprocessing vs waiting list for posttraumatic stress disorder in patients with a psychotic disorder: A randomized clinical trial. JAMA Psychiatry, 72(3), 259–267. https://doi.org/10.1001/jamapsychiatry.2014.2637



























0 Comments